Prognostic stratification of de novo AML patients from the ICAL cohort
| Group . | Stratification criteria . |
|---|---|
| Low risk | t(8;21)(q22;q22); RUNX1-RUNX1T1 |
| inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11 | |
| Mutation in NPM1 without FLT3-ITD | |
| Biallellic mutations in CEBPA* | |
| Intermediate risk | Mutations in NPM1 with FLT3-ITD |
| Wild type for both NPM1 and FLT3-ITD | |
| t(9;11) (p22;q23); MLLT3-MLL | |
| Cytogenetic abnormalities not classified as favorable or adverse | |
| High risk | inv(3)(q21q26.2) or t(3;3)(q21;q26.2);RPN1-EVI1 |
| t(6;9)(p23;q34); DEK-NUP214 | |
| t(v;11)(v;q23); MLL partners | |
| t(9;22)(q34,q11); BCR-ABL1† | |
| -5 or del(5q) | |
| -7 | |
| abn(17p) | |
| Complex karyotype (defined by presence of >3 abnormalities)† | |
| Monosomal karyotype‡ | |
| Mutation in FLT3-ITD without NPM1 | |
| Total white blood cell count >50 × 109/L†,§ |
| Group . | Stratification criteria . |
|---|---|
| Low risk | t(8;21)(q22;q22); RUNX1-RUNX1T1 |
| inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11 | |
| Mutation in NPM1 without FLT3-ITD | |
| Biallellic mutations in CEBPA* | |
| Intermediate risk | Mutations in NPM1 with FLT3-ITD |
| Wild type for both NPM1 and FLT3-ITD | |
| t(9;11) (p22;q23); MLLT3-MLL | |
| Cytogenetic abnormalities not classified as favorable or adverse | |
| High risk | inv(3)(q21q26.2) or t(3;3)(q21;q26.2);RPN1-EVI1 |
| t(6;9)(p23;q34); DEK-NUP214 | |
| t(v;11)(v;q23); MLL partners | |
| t(9;22)(q34,q11); BCR-ABL1† | |
| -5 or del(5q) | |
| -7 | |
| abn(17p) | |
| Complex karyotype (defined by presence of >3 abnormalities)† | |
| Monosomal karyotype‡ | |
| Mutation in FLT3-ITD without NPM1 | |
| Total white blood cell count >50 × 109/L†,§ |
Biallelic mutations in CEBPA were investigated only in 24 samples; all were negative.
Modifications to the proposed European LeukemiaNet 2010.1
Defined by the presence of 1 single monosomy in association with ≥1 additional monosomy or structural chromosome abnormality, excluding core-binding factor leukemia.
In the absence of core-binding factor rearrangements, biallelic mutation of CEBPA or mutation in NPM1 with FLT3-ITD wild type.